TFX Teleflex Incorporated

Teleflex Announces Third Quarter 2024 Earnings Conference Call Information

Teleflex Announces Third Quarter 2024 Earnings Conference Call Information

WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, October 31, 2024.

To participate in the conference call, please utilize this to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, .

An audio replay of the call will be available beginning at 11:00 am Eastern Time on October 31, 2024, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The conference ID is 69028.

About Teleflex Incorporated

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit .

Contacts:

Teleflex Incorporated:

Lawrence Keusch

Vice President, Investor Relations and Strategy Development



610-948-2836





EN
17/10/2024

Underlying

TFXTeleflex Incorporated

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

 PRESS RELEASE
Free
TFX Teleflex Incorp...

First Patient Enrolled in Teleflex’s Barrigel™ Rectal Spacer Trial for...

First Patient Enrolled in Teleflex’s Barrigel™ Rectal Spacer Trial for Post Radical Prostatectomy Radiation Therapy (PPRT) Randomized, controlled study will be first in personalized spacing evidence to include patients who have a prostate cancer recurrence after prostatectomy. WAYNE, Pa., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the first patient enrolled in the latest Barrigel™ rectal spacer randomized, controlled, single-blinded multicenter study: The PPRT Trial. Barrigel™ rectal spacer is ...

October 29, 2024 1 EN
 PRESS RELEASE
Free
TFX Teleflex Incorp...

Teleflex launches next-generation Arrow™ VPS Rhythm™ DLX Device and Na...

Teleflex launches next-generation Arrow™ VPS Rhythm™ DLX Device and NaviCurve™ Stylet in Canada WAYNE, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the launch of two new devices in Canada designed to enhance PICC insertion procedures and reduce the chance of complications. The next-generation Arrow™ VPS Rhythm™ DLX Device and NaviCurve™ Stylet are engineered to work together to give Vascular Access professionals more efficient and predictable PICC placement. The next-generation VPS Rhythm™ DLX...

October 23, 2024 1 EN
 PRESS RELEASE
Free
TFX Teleflex Incorp...

New Data Presented at ASTRO 2024 Further Demonstrate the Safety and Ef...

New Data Presented at ASTRO 2024 Further Demonstrate the Safety and Efficacy of Barrigel™ Rectal Spacer, the First and Only Sculptable Hyaluronic Acid Rectal Spacer, in Patients Undergoing Radiation Therapy for Prostate Cancer(1-3) •   Barrigel™ rectal spacer provides high quality rectal spacing, enabling low dose to the rectum during prostate cancer radiation therapy, with an excellent toxicity and safety profile; and low incidence (0.32-1%) of rectal wall infiltration (RWI), which can be safely reversed using hyaluronidase4,5 •   Data demonstrate safety and efficacy of Barrigel™ rectal...

October 17, 2024 1 EN
 PRESS RELEASE
Free
TFX Teleflex Incorp...

Teleflex Announces Third Quarter 2024 Earnings Conference Call Informa...

Teleflex Announces Third Quarter 2024 Earnings Conference Call Information WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, October 31, 2024. To participate in the conference call, please utilize this to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, . An audio replay of the call will be available beginning at 11:00 am Easte...

October 17, 2024 1 EN
 PRESS RELEASE
Free
TFX Teleflex Incorp...

Teleflex’s Barrigel Rectal Spacer to Be Featured in Three Presentation...

Teleflex’s Barrigel Rectal Spacer to Be Featured in Three Presentations at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting • Highlights include new safety and efficacy data of Barrigel™ rectal spacer, the first and only sculptable rectal spacer1-3 • Teleflex to host Barrigel™ Educational Symposium featuring a physician panel discussion on the Science of Personalized Spacing with Barrigel™ rectal spacer WAYNE, Pa., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced three clinical...

September 26, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch